PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

Completed · Phase 2 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease

In brief

The purpose of this study is to evaluate the safety and efficacy of inhaled PT005 MDI compared to placebo and Foradil Aerolizer in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Key facts

Study ID

NCT01349868

Run by

Pearl Therapeutics, Inc.

People needed

50

Starts

2011-05-01

Expected to finish

2011-07-01

Last updated by the study team

2012-09-12

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Pearl Investigative Site — Clearwater, Florida, United States
• Pearl Investigative Site — Tampa, Florida, United States
• Pearl Investigative Site — Spartanburg, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.